Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:43 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Effect of AQW051 in Patients With Memory Impairment
NCT00582855 · Novartis Pharmaceuticals · PHASE2 · terminated · last registry update 2016-04-19 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CHRNA7 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2016-06-16Also stopped (terminated): University of Colorado, Denver, DMXB-A 150 mg + DMXB-A 75 mg (NCT02111551)
- 2016-02-05Results posted on the registry: VA Office of Research and Development, Pharmacokinetic (NCT00952393)
- 2015-10-15Also stopped (withdrawn): FORUM Pharmaceuticals Inc, EVP-6124 (NCT02246075)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision